This is a working overview of HGF/c-Met, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-25 and is reviewed periodically as new material appears.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
=== Infections === Certain viral and bacterial infections have been linked to autoimmune diseases. For instance, research suggests that the bacterium that causes strep throat, Streptococcus pyogenes, might trigger rheumatic fever, an autoimmune response affecting the heart. Similarly, some studies propose a link between the Epstein–Barr virus, responsible for mononucleosis, and the subsequent development of multiple sclerosis or lupus.
In February 2014, Bhabha Atomic Research Centre (BARC), in Mumbai, India, presented their latest design for a "next-generation nuclear reactor" that burns thorium as its fuel core, calling it the Advanced Heavy Water Reactor (AHWR). In 2009, the chairman of the Indian Atomic Energy Commission said that India has a "long-term objective goal of becoming energy-independent based on its vast thorium resources." On 16 June 2023 China's National Nuclear Safety Administration issued a licence to the Shanghai Institute of Applied Physics (SINAP) of the Chinese Academy of Sciences to begin operating the TMSR-LF1, 2 MWt liquid fuel thorium-based molten salt experimental reactor which was completed in August 2021. China is believed to have one of the largest thorium reserves in the world. The exact size of those reserves has not been publicly disclosed, but it is estimated to be enough to meet the country's total energy needs for more than 20,000 years.
=== Brand names === As of 2018, the combination is marketed under several brand names, including Efficib, Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, Velmetia, Istamet, Emsita, Sitaglyn, Sitazit-M, and Zaxoran.
There is great variation in the carbon isotope composition of amino acids within a single organism. In cyanobacteria, Macko et al. observed a ~30‰ range in δ13C values amongst the amino acids. Amino acids produced from the same precursors also had widely varying compositions. It is difficult to explain these trends because of limited data on the kinetic isotope effects associated with reactions that synthesize amino acid carbon skeletons. Nevertheless, some insights can be gained by applying the logic above to the reaction networks responsible for amino acid biosynthesis. Consider the amino acids synthesized from pyruvate. Pyruvate is produced during glycolysis and can be decarboxylated by pyruvate dehydrogenase to generate acetyl groups. These acetyl groups enter the citric acid cycle as acetyl-CoA or can be used to synthesize lipids. There is a large kinetic isotope effect associated with this reaction, so the remaining pyruvate pool becomes enriched in 13C relative to the acetyl groups. This enriched pyruvate can be transaminated to produce alanine. In the experiments by Macko et al., alanine indeed had a δ13C value slightly higher than that of cyanobacterial photosynthate. Valine is synthesized by the addition of a 13C depleted acetyl group to pyruvate. Consistent with this mechanism, Takano et al. found valine to be depleted in 13C relative to alanine in anaerobic methanotrophic archaea. However, in cyanobacteria, Macko et al. observed a higher δ13C value for valine than alanine.
which gives the area in terms of the diagonals p, q and the sides a, b, c, d of the tangential quadrilateral. The area can also be expressed in terms of just the four tangent lengths. If these are e, f, g, h, then the tangential quadrilateral has the area
Sources: en.wikipedia.org
== Design == Adam Foster, Minerva's designer, is critical of Valve's design of Half-Life 2 maps. His belief is that game developers focus on creating gameplay friendly environments that do not work in an architectural way, "a series of unconnected boxes" says Foster, Minerva's environments are built as actual environments (with correctly proportioned structures and areas) with gameplay worked in later. This creates a more open design, in which players may, in places, navigate in multiple ways. Later locations can be seen in earlier stages of the game (along corridors or through windows for example). Map design is the mod's hallmark. While all levels are constructed primarily using Valve's resources, with few new models or textures, Foster follows his own design ideals – that of compact, well designed maps. Although the levels seem huge, as play unfolds, they are in fact very small - wrapping around to use the least space possible. This creates a sense of realism. As pointed out by Planet Half-Life: "Instead of relying on horizontally-sprawling, immense maps that stress the engine's area-capabilities to its max, Minerva maps are incredibly small. This is because of Foster's ground-breaking idea to utilize every possible area to its maximum potential, and instead of expanding horizontally, he expands vertically." As a result, Minerva maps have a much shorter load time than maps in the original game. Foster creates the maps in layers.
Some phytochemicals found in herbs and fruits can adversely interact with others and over the counter or prescription medications, among other ways by affecting their metabolism by the body. Herbs and fruits that inhibit or induce the body's Cytochrome P450 enzyme complex function can either cause the drug to be dangerously ineffective, or increase its effective absorbed dose to potentially toxic levels, respectively. Best known examples of adverse herb‑drug interactions are grapefruit or St John's wort, contraindicated for several medications including Paxlovid and oral contraceptives, but other herbs also affect the CYP enzyme family, showing herb‑drug interactions.
=== Elderly === An increasing trend of anorexia among the elderly, termed "Anorexia of Aging", is observed, characterized by behaviors similar to those seen in typical anorexia nervosa but often accompanied by excessive laxative use. Most geriatric anorexia patients limit their food intake to dairy or grains, whereas an adolescent anorexic has a more general limitation. This eating disorder that affects older adults has two types – early onset and late onset. Early onset refers to a recurrence of anorexia in late life in an individual who experienced the disease during their youth. Late onset describes instances where the eating disorder begins for the first time late in life. The stimulus for anorexia in elderly patients is typically a loss of control over their lives, which can be brought on by many events, including moving into an assisted living facility. This is also a time when most older individuals experience a rise in conflict with family members, such as limitations on driving or limitations on personal freedom, which increases the likelihood of an issue with anorexia. There can be physical issues in the elderly that leads to anorexia of aging, including a decline in chewing ability, a decline in taste and smell, and a decrease in appetite. Psychological reasons for the elderly to develop anorexia can include depression and bereavement, and even an indirect attempt at suicide.
=== Democratic primary === Caitlin Rourk, Democratic Nominee for the 10th Congressional District, grew up near Washington, D.C., as the daughter of two public school teachers. She served as an intelligence officer in the Texas Army National Guard and U.S. Army Reserve, participating in full-time missions supporting disaster response, border operations, and public health programs. Early in her career, Rourk engaged in bipartisan public policy work focused on deficit reduction and energy security, later leading corporate communications at Dell Technologies. A resident of Central Texas for over a decade, she lives in the Eanes Independent School District, where her children attend public school. Rourk is the Democratic nominee running to represent Texas's 10th Congressional District in the 2026 election, winning her primary with more than 60% of the vote for an open seat created by the retirement of long-serving Republican Representative Michael McCaul. The newly drawn district encompasses 13 counties, stretching from the Houston suburbs through rural East Texas to northern Austin. Positioning herself as a pragmatic problem solver and servant leader, Rourk has centered her campaign on grassroots door-knocking, deep organizing, and restoring accountability through proposals such as mandating regular open town halls in every congressional district.
The fat humps of camels are a source of meat in some cultures. Khlii, a camel meat dish from Algeria, is prepared in a mixture of fat from the camel's hump and kidneys. Camel hump fat is high in saturated fatty acids, with as much as 64.4% of the hump's weight basis consisting of them, and another 33.1% of its weight basis is monounsaturated fats. Bison humps, despite consisting of muscle instead of fat, are also considered a delicacy by some; William Temple Hornaday called sliced and fried bison hump "a dish fit for the gods".In markets where zebu are valued, humps can provide the breeder with higher income. In such markets, cattle may be selectively bred to have a large hump, so as to indicate a pure zebu bloodline. Siddi breeders backcross herds that have mixed too much with humpless cattle, selcting for taller bulls with larger humps, as these will be worth more than humpless bulls. Certain landforms may be named due to their resemblance of animal humps. Camel's Hump in Vermont and Buffalo Hump in Idaho are two such examples. Humans may also take their names from animal humps, such as the Comanche war chief Buffalo Hump. Some HIV-1 patients develop a fat deposit nicknamed a "buffalo hump", though this forms on the patient's neck, as opposed to between the shoulders in an actual bison.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.